6. パーキンソン病 Parkinson disease Clinical trials / Disease details

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

8 trials found

diseases per page:

Showing 1 to 8 of 8 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCTs031190115	11/10/2019	11/10/2019	PK & PD of coadministration of XOR inhibitor and inosine	Pharmacokinetics and pharmacodynamics study of coadministration of either allopurinol or febuxostat ...	Parkinson's disease neurodegenerative disease	Coadministration of allopurinol and inosine, or coadministration of febuxostat and inosine	Kamatani Naoyuki	NULL	Complete	>= 20age old	<= 40age old	Male	28	Phase 1	Japan
2	JPRN-UMIN000030930	2018/01/29	01/01/2019	Study on efficacy and safety of the simultaneous treatment with febuxostat and inosineof patients wi ...	Study on efficacy and safety of the simultaneous treatment with febuxostat and inosineof patients wi ...	Parkinson's disease	Administration of febuxostat 20 mg and inosine 500 mg twice a day for 58 days	StaGen Co. Ltd.	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	30	Not selected	Japan
3	JPRN-UMIN000024312	2016/09/20	25/05/2017	Studies of efficacy and safety of the combined use of febuxostat and inosinefor patients with Alzhei ...	Studies of efficacy and safety of the combined use of febuxostat and inosinefor patients with Alzhei ...	Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis or multiple sclerosis	Treatment with febuxostat 20 mg and inosine 0.5 g, twice a day for 2 weeks	Tsukuba International Clinical Pharmacology Clinic	NULL	Complete: follow-up complete	20years-old	80years-old	Male and Female	12	Not selected	Japan
4	NCT02642393 (ClinicalTrials.gov)	June 2016	19/12/2015	Study of Urate Elevation in Parkinson's Disease, Phase 3	A Randomized, Double-blind, Placebo-controlled Trial of Urate-elevating InosineTreatment to Slow Cli ...	Parkinson's Disease	Drug: Inosine;Drug: Placebo	Michael Alan Schwarzschild	The Parkinson Study Group;Michael J. Fox Foundation for Parkinson's Research;University of Rochester ...	Completed	30 Years	N/A	All	298	Phase 3	United States;Puerto Rico
5	JPRN-UMIN000009062	2016/05/30	09/10/2012	An open-label, single-centered, non-randomized trial of inosineto assess its safety for patients wit ...	An open-label, single-centered, non-randomized trial of inosineto assess its safety for patients wit ...	Parkinson's disease	Take oral inosine 500-3000mg/day to achieve a serum UA level between 6.0-8.0 mg/dL	Dept. of Clinical pharmacology and Neurology	NULL	Complete: follow-up complete	20years-old	Not applicable	Male and Female	20	Phase 1	Japan
6	JPRN-jRCTs061180060	22/03/2016	18/03/2019	Randomized clinical trial to assess the disease modifying effect of oral inosinefor patients with Pa ...	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of ...	Parkinson's disease;D010300	Inosine to maintain a serum urate level between 6.0-7.5 mg/dL for 2 years or placebo (500mg/CP)	Nagai Masahiro	NULL	Complete	>= 20age old	Not applicable	Both	100	Phase 2	Japan
7	JPRN-UMIN000020527	2016/02/01	01/02/2016	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of ...	Multi-centered, placebo-controlled, double-blind, randomized clinical trial to assess the effect of ...	Parkinson's disease	Inosineto maintain a serum uratelevel between 6.0-7.5 mg/dL for 2 years Lactoseas a placebo for 2 yea ...	Ehime University Graduate School of Medicine	NULL	Recruiting	20years-old	Not applicable	Male and Female	100	Phase 2	Japan
8	NCT00833690 (ClinicalTrials.gov)	June 2009	27/1/2009	Safety of Urate Elevation in Parkinson's Disease	A Randomized, Double-blind, Placebo-controlled, Dose-ranging Trial of Oral Inosineto Assess Safety a ...	Parkinson Disease	Drug: Placebo;Drug: inosine	The Parkinson Study Group	Massachusetts General Hospital;Harvard School of Public Health;University of Rochester;Michael J. Fo ...	Completed	30 Years	N/A	All	75	Phase 2	United States

First Previous1Next Last